Metabarbital - General Information:Metabarbital was patented in 1905 by Emil Fischer working for Merck. It was marketed as Gemonil by Abbott Laboratories. It is a barbiturate anticonvulsant, used in the treatment of epilepsy. It has similar properties to phenobarbital.
Other Brand Names containing Metharbital
Metabarbital - Pharmacology:
Metabarbital binds at a distinct binding site associated with a Cl- ionopore at the GABAA receptor, increasing the duration of time for which the Cl- ionopore is open. The post-synaptic inhibitory effect of GABA in the thalamus is, therefore, prolonged. All of these effects are associated with marked decreases in GABA-sensitive neuronal calcium conductance (gCa). The net result of barbiturate action is acute potentiation of inhibitory GABAergic tone. Barbiturates also act through potent (if less well characterized) and direct inhibition of excitatory AMPA-type glutamate receptors, resulting in a profound suppression of glutamatergic neurotransmission.
Metabarbital for patients
Data is temporarily not available
Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), anticoagulants (blood thinners), carbamazepine, corticotropin (barbiturates may decrease the effects of these medicines), central nervous system (CNS) depressants (using these medicines with barbiturates may result in increased CNS depressant effects), divalproex sodium, valproic acid (using these medicines with barbiturates may change the amount of either medicine that you need to take), and oral contraceptives (birth control pills) containing estrogens (barbiturates may decrease the effectiveness of these oral contraceptives, and you may need to change to a different type of birth control).
The following conditions may affect the use of barbiturates: alcohol abuse (or history of), history of/current drug abuse or dependence (dependence on barbiturates may develop), anemia (severe), asthma (history of), emphysema, or other chronic lung disease, diabetes mellitus (sugar diabetes), hyperactivity (in children), mental depression, overactive thyroid, porphyria (barbiturates may make the condition worse), kidney disease, liver disease (higher blood levels of barbiturates may result, increasing the chance of side effects), pain (barbiturates may cause unexpected excitement or mask important symptoms of more serious problems), underactive adrenal gland (barbiturates may interfere with the effects of other medicines needed for this condition).
Indication, Mechanism Of Action, Drug Interactions, Food Interactions, etc..